# EDGAR Filing Document

**Accession Number:** 0000893949
**File Stem:** 0001193125-26-212117
**Filing Date:** 2026-5
**Character Count:** 8853
**Document Hash:** 9a0c2e5999d424211b5c9cb441236675
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-212117.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001193125-26-212117

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20260507

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pediatrix Medical Group, Inc.
- **CENTRAL INDEX KEY:** 0000893949
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HOSPITALS [8060]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 263667538
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12111
- **FILM NUMBER:** 26954049

**BUSINESS ADDRESS:**
- **STREET 1:** 1301 CONCORD TERRACE
- **CITY:** SUNRISE
- **STATE:** FL
- **ZIP:** 33323
- **BUSINESS PHONE:** 9543840175

**MAIL ADDRESS:**
- **STREET 1:** 1301 CONCORD TERRACE
- **CITY:** SUNRISE
- **STATE:** FL
- **ZIP:** 33323

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MEDNAX, INC.
- **DATE OF NAME CHANGE:** 20090102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PEDIATRIX MEDICAL GROUP INC
- **DATE OF NAME CHANGE:** 19950801

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** May 07, 2026<br>

------

![img89869879_0.jpg](img89869879_0.jpg)

Pediatrix Medical Group, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Florida | 001-12111 | 26-3667538 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 1301 Concord Terrace |  |  |
| Sunrise**,** Florida |  | 33323 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 954 384-0175<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | |
|:---|:---|
| **<br>Title of each class** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $.01 per share<br> MD | The New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As disclosed under Item 5.07 of this Current Report on Form 8-K, at the 2026 Annual Shareholders' Meeting (the "Annual Meeting") of Pediatrix Medical Group, Inc., a Florida corporation (the "Company"), held on May 7, 2026, the shareholders of the Company approved the Company's Second Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), which, among other things, increased the number of shares of the Company's common stock available for issuance under the Plan by 8,000,000 shares.

The Plan is described in greater detail in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on March 27, 2026, under the heading "Proposal 4: Approval of the Pediatrix Medical Group, Inc. Second Amended and Restated 2008 Incentive Compensation Plan" and such description is incorporated by reference herein.

The foregoing description of the Plan is only a summary, and is qualified in its entirety by reference to the full text of the Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

## Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 7, 2026, the Company held the Annual Meeting. Of the 83,072,104 shares of common stock outstanding and entitled to vote, 77,330,139 shares were represented, constituting a quorum. The final results for each of the matters submitted to a vote of the Company's shareholders at the Annual Meeting are as follows:

Proposal 1: All of the nominees for the Company's Board of Directors were elected to serve until the Company's 2027 Annual Shareholders' Meeting or until their respective successors are elected and qualified, by the votes set forth in the table below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **For** | **Against** | **Abstained** | **Broker <br>Non-Vote** |
| &nbsp;&nbsp;Laura A. Linynsky | 71249187 | 967057 | 18087 | 5095808 |
| &nbsp;&nbsp;Thomas A. McEachin | 70107436 | 2093168 | 33727 | 5095808 |
| &nbsp;&nbsp;Kurt D. Newman, M.D. | 71922039 | 256292 | 56000 | 5095808 |
| &nbsp;&nbsp;Mark S. Ordan | 69958141 | 2259130 | 17060 | 5095808 |
| &nbsp;&nbsp;Michael A. Rucker | 70689577 | 1523843 | 20911 | 5095808 |
| &nbsp;&nbsp;Guy P. Sansone | 70738837 | 1475369 | 20125 | 5095808 |
| &nbsp;&nbsp;John M. Starcher, Jr. | 46296745 | 25909618 | 27968 | 5095808 |
| &nbsp;&nbsp;Shirley A. Weis | 70725919 | 1478539 | 29873 | 5095808 |
| &nbsp;&nbsp;Sylvia J. Young | 71257572 | 963152 | 13607 | 5095808 |

---

Proposal 2: The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the 2026 fiscal year was ratified by the Company's shareholders, by the votes set forth in the table below:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstained** | **Abstained** | **Broker<br>Non-Vote** | **Broker<br>Non-Vote** |
|  | 75,519,473 |  | 1,794,278 |  | 16,388 |  | 0 |

---

Proposal 3: The Company's shareholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the 2025 fiscal year, by the votes set forth in the table below:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstained** | **Abstained** | **Broker<br>Non-Vote** | **Broker<br>Non-Vote** |
|  | 70,257,832 |  | 1,960,931 |  | 15,568 |  | 5,095,808 |

---

Proposal 4: The Plan was approved by the Company's shareholders, by the votes set forth in the table below:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstained** | **Abstained** | **Broker<br>Non-Vote** | **Broker<br>Non-Vote** |
|  | 65,912,243 |  | 6,303,675 |  | 18,413 |  | 5,095,808 |

---

------

## Item 9.01 Financial Statements and Exhibits.
**d) Exhibits.** 

**Exhibit Index**

---

| | |
|:---|:---|
| 10.1 | [<u>Pediatrix Medical Group, Inc. Second Amended and Restated 2008 Incentive Compensation Plan (incorporated by reference to Exhibit A to the Company's Definitive Proxy Statement on Schedule 14A, filed with the SEC on March 27, 2026).</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/893949/000119312526127299/md-20260325.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document).<br>|

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **Pediatrix Medical Group, Inc.**  |
| Date: | May 7, 2026 | By:  | /s/ Kasandra H. Rossi |
|  |  |  | Kasandra H. Rossi<br>Chief Financial Officer |

---

------